Wells Fargo & Company MN Grows Stake in Regenxbio Inc (RGNX)

Wells Fargo & Company MN grew its holdings in Regenxbio Inc (NASDAQ:RGNX) by 174.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,473 shares of the biotechnology company’s stock after purchasing an additional 28,264 shares during the quarter. Wells Fargo & Company MN’s holdings in Regenxbio were worth $1,465,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the company. Redmile Group LLC grew its position in shares of Regenxbio by 35.4% in the second quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock valued at $33,944,000 after purchasing an additional 449,540 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Regenxbio by 3.5% during the third quarter. JPMorgan Chase & Co. now owns 1,270,327 shares of the biotechnology company’s stock valued at $40,778,000 after buying an additional 43,492 shares during the period. Vanguard Group Inc. lifted its stake in shares of Regenxbio by 10.3% during the second quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock valued at $21,379,000 after buying an additional 100,944 shares during the period. Citadel Advisors LLC lifted its stake in shares of Regenxbio by 65.4% during the second quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock valued at $18,292,000 after buying an additional 366,289 shares during the period. Finally, GMT Capital Corp lifted its stake in shares of Regenxbio by 47.3% during the third quarter. GMT Capital Corp now owns 898,067 shares of the biotechnology company’s stock valued at $29,591,000 after buying an additional 288,367 shares during the period. Institutional investors and hedge funds own 68.73% of the company’s stock.

Regenxbio Inc (NASDAQ:RGNX) opened at $27.10 on Friday. Regenxbio Inc has a one year low of $16.30 and a one year high of $36.45.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.04. The company had revenue of $1.34 million for the quarter. Regenxbio had a negative net margin of 764.06% and a negative return on equity of 39.33%. research analysts forecast that Regenxbio Inc will post -2.83 earnings per share for the current year.

Several equities analysts recently issued reports on the stock. Raymond James Financial reissued a “buy” rating on shares of Regenxbio in a research note on Friday, January 5th. Bank of America reissued a “buy” rating and set a $38.00 price objective (up previously from $33.00) on shares of Regenxbio in a research note on Monday, October 9th. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a research note on Wednesday, October 18th. Chardan Capital reissued a “buy” rating on shares of Regenxbio in a research note on Monday, December 11th. Finally, BidaskClub raised shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a research note on Friday, December 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $42.43.

In other Regenxbio news, CFO Vittal Vasista sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $30.16, for a total transaction of $150,800.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Curran Simpson sold 2,000 shares of the stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $29.31, for a total transaction of $58,620.00. Following the transaction, the senior vice president now directly owns 41,500 shares in the company, valued at approximately $1,216,365. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 84,000 shares of company stock worth $2,605,796. 17.00% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Wells Fargo & Company MN Grows Stake in Regenxbio Inc (RGNX)” was published by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/wells-fargo-company-mn-grows-stake-in-regenxbio-inc-rgnx/1849610.html.

About Regenxbio

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August


Leave a Reply

 
© 2006-2018 BBNS.